Ethical issues and GenomEUtwin by Harris, J.R. et al.
455Twin Research Volume 6  Number 5  pp. 455–463
The post-genomic era is witnessing a proliferation of large-scale and population based genetic and genomic research
projects. Many countries have or are establishing research
biobanks and, as with GenomEUtwin, there is great interest in
building multinational projects that link genotypic and pheno-
typic information from different centers. Clearly, the conduct of
these projects raises multiple ethical issues, and the knowl-
edge generated will continually recast the ethical, legal and
social implications (ELSI) of such research. Maximising the 
scientific profit from this work while minimizing the risks to the
participants requires full integration of ethics components into
the structure and functioning of these projects. GenomEUtwin
is organized around five intellectual cores, including an Ethics
Core which operates across the entire project. This paper
describes the role of the Ethics Core and presents an overview
of the guidelines on which the principles followed in
GenomEUtwin are based. We outline the major ethical con-
cerns of our project and highlight complexities arising from
diverse national legislations. Finally, the role of empirically
based ethics research is discussed for understanding the
ethical, legal, social and economic implications of human
genetics and genomics research. 
Large-scale genomics research promises to help elucidate
how biological systems function and interact with a host of
environmental factors, both in healthy development and in
the pathogenesis of disease. Novel methodological
approaches coupled with faster and cheaper genotyping and
phenotyping tools will generate information critical to
understanding disease etiology, diagnosis, and the tailoring
of treatment and prevention. In these endeavors popula-
tion-based studies, such as GenomEUtwin, are critical to
identify predisposing alleles and verify their significance in
the population at hand as well as for exploring gene-envi-
ronment interactions. However, these advances carry the
potential to undermine the very paradigms and technolo-
gies upon which they are built if the resulting genetic
information is misused (e.g., health-insurance discrimina-
tion) or causes detriment to individuals, families and
society. This was recognized from the beginning by the
planners of the Human Genome Project (HGP) who devel-
oped an ethical, legal and social implications (ELSI)
program to promote research, education and outreach sur-
rounding ethical, legal and social issues of human genetic
and genomic research.1
Although the importance of articulating ELSI issues is
receiving increased attention, neither empirical investiga-
tions into the most urgent ethical issues, nor the
establishment of ethical procedures used in empirical
research has been able to keep pace with the unprecedented
acceleration in genomics technology. This arises, in part,
because the post-genomic era is confronting individuals,
families, societies, policy makers, politicians, legal experts,
educators and researchers with unforeseen problems and
concerns. Optimizing genetic and genomic knowledge
accompanied by minimizing risk is a complicated task.
There is considerable context dependency associated with,
for example, sociocultural factors, the genetic basis of the
disease under study, age, national health care and legal
systems and our knowledge of etiology and treatment. For
instance, when prevention is possible, as in the single gene
disorder PKU, ethical concerns about testing for individu-
als at risk are straightforward and neonatal screening is
widely acceptable. 
Nevertheless, knowledge generated from these studies
will raise new and specific ethical issues that require full
integration of genetics and genomics into public health
research agendas (Beskow, 2001). Some of the ethical issues
are common across studies and underline the need for har-
monizing guidelines and regulatory frameworks in order to
pursue international projects. Other issues may be more
specific to each study and researchers will need to evaluate
such potential in the planning and development phases of
their studies. For example, GenomEUtwin poses unique
questions because an identical twin who consents to geno-
typing has, de facto, provided DNA for their co-twin. 
GenomEUtwin currently includes research centers from
Australia, Denmark, Finland, Italy, the Netherlands,
Norway, Sweden, and the United Kingdom. The purpose
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of this paper is to provide an overview of the ethical issues
that confront such multinational genetic and genomic pro-
jects and to describe the approaches adopted by
GenomEUtwin for handling these issues. First we describe
the role of the Ethics Core associated with our project, then
we summarize European and other guidelines which
provide the backdrop for the principles followed in
GenomEUtwin. Next we outline the major ethical concerns
of our project and highlight complexities arising from
diverse national legislations. Finally, the importance of
empirically-based ethics research is discussed in order to
further our understanding of the ethical, legal, social and
economic implications of genetics and genomics research. 
The GenomEUtwin Ethics Core
As described elsewhere in this volume the main research
goal of GenomEUtwin is to identify genes that predispose
to common diseases. A project of this magnitude, with
study samples being collected in several countries, poses
multiple ethical dilemmas. An EC regulatory framework
does not yet exist for ethical issues and consent for genetic
studies. To help address and implement the ethical issues
raised in this project an Ethics Core was established as an
integral component of GenomEUtwin. The Ethics Core is
composed of representatives from each participating center
who are knowledgeable about their respective country’s
ethics code, and is reinforced by internationally acknowl-
edged experts in medical ethics and biobanking.2The
principles followed by the Ethics Core for addressing key
ethical issues related to data collection, storage, consent, use
of samples and secondary use of samples are based upon a
number of documents as articulated in the next section.
A key activity of the Ethics Core is to harmonize ethics
protocols across centers and make public the procedures and
products related to our activities. This involves identifying
commonalities and differences between the participating
countries regarding ethical regulations (e.g., informed
consent) so that our procedures and products (e.g., consent
forms) can be standardized yet modifiable in accordance
with national regulations. Such information will be used to
formulate templates for informed consent and for research
applications for approval by local ethics boards. These
forms, along with the ethical guidelines, will be published in
a project ethics manual and posted on the project website
along with other background information. The Ethics Core
will keep track of the local ethics committees’ authorizations
and opinions and give advice to local centers when applying
for local approval, if requested. In conjunction with local
ethics committees the Ethics Core will also develop proce-
dures to handle special circumstances that may lead to
release of genetic results to certain participants.
Many of our ethics related procedures are still in the
developmental phase, but project after project is faced with
the same ethical issues and concerns; the development 
of standardized guidelines will greatly facilitate the type 
of genetic research and biobanking procedures that will 
be necessary to elucidate the etiology of complex disease. 
A unique feature of GenomEUtwin is the prospective cardio-
vascular cohort component: MORGAM. The rationale
behind its inclusion is that candidate genes for cardiovascular
disease identified in the twin studies can be tested prospec-
tively within MORGAM. The tasks of our Ethics Core will
benefit enormously from the work already completed and
the ethics manual generated from our partners associated
with the MORGAM project. MORGAM has developed
other tools such as a standardized Ethical Clearance Letter
which must be produced to lend assurance to the
Coordinators that the necessary ethical safeguards are in
place, and a simple Material and Data Transfer Agreement
which must be completed before the shipping of data and
samples to the central laboratory, or between the central
laboratories and other participating laboratories. It is
planned that the Material and Data Transfer Agreement
developed in MORGAM will be adopted for use more gen-
erally within GENOMEUTWIN.3 Training young
scientists and researchers on the project also comes under
the auspices of the Ethics Core. This includes organizing
ethics modules for courses in our training and mobility
component and working to foster networks between
groups, with established expertise in bioethics, and the par-
ticipating centers. The Core will meet whenever necessary;
however, at least once a year a meeting is held with special
emphasis placed on ethics training of young scientists par-
ticipating in the Project. 
The Ethics Core is also instrumental in forging research
networks that connect researchers associated with
GenomEUtwin with experts in ethics and related fields.
Along these lines the Ethics Core writes proposals applying
for supplemental research funds to recruit young scientists
who can help develop and conduct newly formulated
research projects investigating ELSI issues.
Overview of Guidelines on Biomedical Research
and Ethics with Special Emphasis 
on Genetic Research and Biobanks
A substantial number of regulations and guidelines exist
concerning bioethics and research and derive from a wide
range of sources ranging from international agencies to
national legislation to statements issued from professional
societies. The sheer number of recent bioethics documents
emanating from these diverse sources illustrates the neces-
sity for standardization and harmonization of ethical
research protocols in genetics. While it is not our purpose
to provide a comprehensive overview of these various docu-
ments, we do present some background information
concerning the documents most essential for the develop-
ment of the European guidelines upon which we base our
ethical procedures in GenomEUtwin. Some of the debate
and concerns raised by these documents illustrates that the
field is far from unified, a situation that many researchers
grapple with in project development. 
For more than 2000 years the medical profession has
regarded the Hippocratic Oath as the gold standard for
good medical conduct. But, biomedical research ethics has
a much shorter history of regulations, the oldest dating to
The Nuremberg Code (1946)4. In 1964 the World Medical
Association (WMA) agreed upon the first Declaration 
of Helsinki5 which provides guidance for all medical
research involving human subjects, including identifiable
human material or identifiable data, including DNA from
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biobanks. It states explicitly that considerations related to
the well-being of the human subject should take prece-
dence over the interests of science and society. The
Declaration distinguishes between research subjects and
patients who can gain from the research versus those who
can not and emphasizes the necessity to view research
without benefit to the research subjects rigorously such that
the absolute risk to subjects participating in research is
minimized. This document has been amended several
times, the latest in 2002.
The Council for International Organizations of Med-
ical Sciences (CIOMS) published in 1982 and updated in
2002 the International Ethical Guidelines for Biomedical
Research Involving Human Subjects.6 These guidelines are
highly congruent with the Helsinki Declaration, although
much more specific and comprehensive. A number of issues
remain controversial (e.g., the necessity for consent and 
of informing patients of their personal results). Currently,
many of these guidelines are used by several European
countries. In response to ethical concerns of particular rele-
vance to epidemiological studies the CIOMS also
developed in collaboration with WHO International
Guidelines for Ethical Review of Epidemiological Studies7,
which were published in 1991.
In 1996 the Council of Europe issued the Convention
for the Protection of Human Rights and Dignity of the
Human Being with regard to Application of Biology and
Medicine: Convention on Human Rights and Medicine.8
Among other things, this convention states that predictive
genetic testing and intervention on the human genome
must only take place based on a health-related indication or
as part of biomedical research. In 2001 the European
Parliament’s Temporary Committee on Human Genetics
and Other New Technologies in Modern Medicine issued a
Report on the ethical, legal, economic and social implica-
tions of human genetics9 that was based upon a background
document and a draft report which had been considered to
be balanced and insightful by many researchers in the field.
However, the final report was quite restrictive with many
amendments and recommendations regarding several highly
debatable issues (e.g., therapeutic cloning) including that
the EU guidelines should have priority over national guide-
lines (i.e., to relinquish the sub- sidiarity principle of the
EU). The report was voted down by the European
Parliament in November 2001.
In 2002 WHO’s Advisory Committee on Health
Research also issued its report on Genomics and World
Health.10 The section on the ethical implications of
genomics is particularly concerned with the risk of dispar-
ity in health care across countries, due to the expense
related to new biotechnology and information technology,
and the risk of neglect of diseases in the poorest countries
of the world.
The completion of the Human Genome Project and its
accompanying explosion in genetic knowledge and research
has created greater interest for access to biological materials
from large numbers of subjects and families. Consequently,
attention is focused on possibilities for storing these
samples (i.e., biobanks). A number of European countries
now have guidelines and opinions issued by medical
research councils or ministries; some of these are referred to
here and those of relevance to the countries participating in
GenomEUtwin are referenced on our web page.
Articulating the ethical issues involved in such biobanks is
not straightforward and has been handled differently by
different countries and projects. For instance, several
research projects have been carried out in Sweden to seek
the kind of biobank management that will satisfy the inter-
est of both the research community and the general public.
Results were recently published in the book Biobanks as
resources for health (Hansson, 2003). The UK Biobank
project, a proposed large-scale study of 500,000 individuals
that will investigate genetic, the environmental and lifestyle
factors on common diseases of adulthood, has followed a
somewhat different route and the deliberations generated
from an ethics consultation workshop held in 200211 will
serve as the basis for developing the ethical framework for
the Biobank. 
In addition to national publications an EU opinion was
released (1998) on Ethical Aspects of Human Tissue
Banking.12 This document represents the opinion of the
European Group on Ethics in Science and New
Technologies regarding: the need to protect health of both
donors and recipients of tissue, respect of bodily integrity of
donors, procuring informed consent, respect of privacy and
confidentiality of information collected, prevention of pos-
sible discrimination and promoting solidarity and tissue
availability in Europe. Furthermore, this Group reserves
tissue banking activities to public health institutions or non-
profit organisations. An EU workshop on optimisation of
biobanks held in Oslo, Norway in January 200313, recom-
mends standardisation of guidelines for exchange of
biological material within Europe, consideration of the wide
European differences when performing ethical review and
informing donors, ethical review of all collections of human
material, bridging historical biobanks with freshly stored
samples and registry data, development of common proto-
cols and support of interdisciplinary European networks.
Areas of Major Ethical Concerns 
and GenomEUtwin
The major ethical issues connected with research studies
that involve the collection and storage of biological samples
originate from the principles of informed consent, storage
of biological samples, data security and protection of the
confidential information relative to donors, and non-trad-
ability of the human body (Deschênes et al., 2001). In
addition, questions of commercialization and providing
feedback to participants need to be addressed in project
planning. 
Informed Consent
Informed consent is a basic tenet of bioethics and an
expression of the fundamental principles of an individual’s
autonomy and respect for freedom. The key documents
that address fundamentals of medical ethics, at national
and international levels (Lenoir & Mathieu, 1998), refer to
the duty to obtain voluntary and informed consent after
providing individuals with appropriate information. For
example, Article 1 of the Nuremberg Code recognizes free
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and informed consent as fundamental to human research
(The Nuremberg Code, 1946). Guidelines on the consent
requirements, in the case of human tissue banks can be
inferred from both generic documents (e.g., the Helsinki
Declaration (World Medical Association, 2000; CIOMS,
2002) and from specific documents on genetic research
(e.g., “Statement on informed consent for genetic research”
of the American Society for Human Genetics, American
Society for Human Genetics, 1996). These documents
basically agree upon the principles identified, with regard
to both consent and the other requirements. 
The principle of consent provides that the individual
will be explicitly informed of the purpose of data collec-
tion, the confidentiality of the data, the measures taken to
protect confidentiality, who will have access to the data, the
transfer and disposal of data, and the potential secondary
use of data. The controller of the data is required to insti-
tute appropriate safeguards for personal data stored for
research use. 
Consent forms for sampling and storage of biological
material shall therefore specify the following:
• possible risks and harms to the participant related to
conduct of the research
• purposes for which samples are taken
• purposes of the storage of samples
• methods and techniques used
• terms under which the confidentiality of the data and
anonymity are granted
• selection of structures for the analyses and storage of
samples
• duration of the storage
• methods of withdrawing consent, if possible or request-
ing to eliminate one’s sample from a human tissue bank
• use of a sample in case of the donor’s death. 
An aspect of consent with peculiar connotations for human
tissue banks, and with which GenomEUtwin may well be
confronted in the future, involves samples for which indi-
viduals are unable to express their consent. This could arise
if individuals die in the course of the research or become
too ill to be able to provide informed consent. The “Con-
vention on Human Rights and Biomedicine” states:
“Where, according to law, an adult does not have the
capacity to consent to an intervention because of a mental
disability, a disease or for similar reasons, the intervention
may only be carried out with the authorization of his or her
representative, or an authority, or a person or body pro-
vided for by law. The individual concerned shall as far as
possible take part in the authorization procedure” (art. 6).
Updating of Consent
An important aspect for any human tissue bank or collec-
tion of genome-wide scans concerns the consent for
potential future applications that were not envisaged at the
initiation at the project. This has particular implications for
GenomEUtwin because of its scientific objectives and the
probability that this platform will serve for many new pro-
jects in the future. A typical scenario may be that new
interests and applications emerge while the original project
is underway; this raises the question of updating consent
procedures. Many documents are explicit in this regard;
among them, reference can be made to the “Convention on
Human Rights and Biomedicine” of the Council of
Europe, which states in article 22 that: “When in the
course of an intervention any part of a human body is
removed, it may be stored and used for a purpose other
than that for which it was removed, only if this is done in
conformity with appropriate information and consent pro-
cedures” (Council of Europe, 1996). This article also
applies to blood samples. Other documents specify a duty
to only use the samples present in human tissue banks only
for the purposes for which consent was given. In this
respect, among the various existing texts, reference should
be made to the document entitled “Ethical aspects of
human tissue banking” of the European Group on Ethics
in Science and New Technologies (European Group on
Ethics, 1998). 
Between country differences exist in the regulations
regarding renewal and updating of consent procedures.
Some countries are currently re-evaluating and reforming
these regulations. For example, in Finland The Act on the
Use of Human Organs and Tissues for Medical Purposes
(2001) allows a tissue sample collected for medical research
to be used for another medical research project, but only if
the research subject has given his or her consent to it.
Therefore, a new consent must be obtained if the original
consent does not cover the new use of the sample.
However, a working group of the Sub-Committee on
Medical Research Ethics of the National Advisory Board on
Health Care Ethics has recently (Autumn 2002) issued a
report on DNA samples in epidemiologic research where
they propose that some national board/committee/author-
ity should be allowed to give consent to further research if
the person who has given the sample can’t be contacted
(with reasonable efforts if they are still alive). So far this
proposal has not led to any concrete legislative proposals,
but this issue will be further considered at the Ministry of
Health. It is possible though to obtain consent for rather
broad definitions (e.g., in Denmark it is not necessary to
specify in the consent form each candidate gene or SNP
that is of interest for study). Thus it is possible after years of
banking the DNA to use it for new tests if these are consid-
ered to be covered by the original broad definition. These
circumstances may, however (depending on the country),
need to be judged by the officially appointed medical ethics
committee prior to the analyses. A related issue is that of
data storage when the proposed analyses are finished. In
many countries the consent form should describe what will
happen with remaining biological samples once the
research has been completed, and it may also be required
that the biological samples are destroyed. Individuals
should be made aware if, and for what reason, biological
material is stored. 
Confidentiality and Risk of Discrimination
Data confidentiality is one of the basic requirements for
research involving humans. The current European legisla-
tions on data confidentiality and security are derived from
directive 95/46/EC of the European Parliament and of the
458 Twin Research October 2003
Jennifer R. Harris, Gonneke Willemsen, Tiina Aitlahti3, Carlo Petrini, Alun Evans, Kaisa Silander, Lia Cirrincione, and Kirsten Ohm Kyvik
Council “on the protection of individuals with regard to
processing of personal data and on the free movement of
such data”, and from recommendation R(97)5 of the
Committee of Ministers to member states “on the protec-
tion of medical data”. The directive requires individuals
consented for a study to be informed on the collection,
processing and storing of personal data. 
Issues of data confidentiality are closely linked to the
ownership of the data. The question “who owns the data?”
is not specifically addressed by most European law and may
differ from US law in this regard, where the biological
sample may still “belong” to the subject. In their recent
guidelines the United Kingdom Medical Research Council
(UK-MRC) states that the UK-MRC may retain the formal
responsibility for large multi-center collections or research-
directed databases, though the day-to-day care for the
databases will remain with the institutions that collected
the data. In this sense the interpretation by the UK-MRC
of the status of personal data may most closely reflect the
intention of most European legislation; tissue samples are
seen as gifts or donations and property rights and control of
the samples are automatically transferred to the recipient of
the gift. However, the donor has the right to restrict the use
of the donation. The EU Directive 95/46/EC states that
personal data need to be governed by one responsible
person or institution. For the countries participating in
GenomEUtwin the institution or university is responsible
for the data, which is preferable because it prevents prob-
lems that may arise if an individual responsible for the data
leaves an institution. Responsibility for the database also
incorporates the obligation to safeguard the confidentiality
of the data. Organisations that maintain databases with
personal information are typically held responsible for the
safety of the data, for instance by encoding the data and
using specialised encrypting software. Although institutions
or individuals are held responsible for the personal data reg-
isters, they are not allowed to share the information with a
third party without informing the individuals involved. An
exception is data which are stored unlinked; that is, infor-
mation on the identification of the individuals is unlinked
from the phenotypic and genotypic data, making it impos-
sible to trace the individual donating the information.
Biological samples may never be sold for a profit but intel-
lectual property rights may be sold or licensed. 
In biological banks where DNA is stored, information
is potentially much broader than was purposely collected
for the initial objectives of the study. Such potential grows
as knowledge in the genetic field develops. Therefore, bio-
logical banks are actually banks of sensitive data, capable of
drawing the attention of many outside interests, with
objectives that are varied and distant from the diagnostic,
therapeutic and research purposes proper for medical and
biological sciences (e.g., insurance companies, banks,
employers, and law enforcement agencies). The operational
criteria which have to be met can be drawn from both more
generic principles expressed in declarations, treaties and
other documents of bioethics (Lenoir & Mathieu, 1998),
and from specific documents, such as “Genetics and
privacy: a patchwork for protection” commissioned by the
California Health Care Foundation (Hustead et al., 2002).
In many countries, this issue is ruled by specific regula-
tions (Byrne, 1997). Some concepts governing the
protection of personal data can be gleaned from the bulk
of these documents:
• monitor the access to data
• supervise the purposes for data storage and use
• control the proportionality between quantity and
quality of the data stored with regard to the aims of
their storage
• check that the storage time does not exceed the neces-
sary period
• grant an individual the access to his/her data and the
possibility to check, integrate or block them
• grant “traceability”: it should be possible to trace the
origin of data and to know the transmission modes. 
Data Confidentiality in GenomEUtwin
In developing the GenomEUtwin databases, issues of data
confidentiality and protection are complicated by diverse
legislation concerning privacy and data confidentiality in
the participating countries. For reasons of data confiden-
tiality GenomEUtwin will separate the phenotypic database
from the genotypic database to ensure greater security of
the data. Genotypic and phenotypic data will only be
merged for analytical purposes, and the ability to do the
analyses will be regulated by the Database and Statistical
Cores, with the permission of the twin registries. 
A central genotypic database will be physically located
at the National Public Health Institute. The genotypic
database will include both microsatellite and single
nucleotide polymorphism marker data, which will be con-
tributed by four genotyping facilities: the Genome Center
and the Department of Molecular Medicine at Uppsala
University, the Finnish Genome Center, and the National
Public Health Institute of Finland. The individual DNA
samples included in the project are labeled with a
GenomEUtwin ID number, which will be different from
internally identifiable data at the respective study centers.
Each twin registry will keep their own internal study IDs
and keys, linking the study IDs to personal identifiers and
other data, will be kept secure under their own security
policies. Genotypic data will be encrypted before transfer
from the genotyping centers to the general GenomEUtwin
genotypic database or to and from the registry centers. All
databases will be protected by firewalls, and will have a
password-protected access. The genetic data will not be
released to participants, except under special circumstances
and in consultation with the local Ethics Committees.
Extensive phenotypic data have been and are being
collected by each twin registry participating in the Genom-
EUtwin project. These data are administrated and secured 
by each respective twin registry (for the latest reference on
the twin registries see Boomsma et al., 2002; Harris et al.,
2002; Hopper, 2002; Kaprio & Koskenvuo, 2002; Pedersen
et al., 2002; Skytthe et al., 2002; Spector & MacGregor,
2002; Stazi et al., 2002). The Database Core is working in 
a stepwise manner to develop a long- term solution to secure
the database. For phenotypic data this entails a two-stage
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process, the first stage is creation of a common data struc-
ture and the transfer of encrypted files to be used in a
prototype database. GenomEUtwin will not construct a
central phenotypic database. Rather, the ultimate goal is the
creation of transient analyses-specific phenotypic databases
that will be analyzed and then deleted at the end of analy-
ses. These transient databases will be encrypted and
password-protected and are only accessible by the
researchers participating in the project. The database core is
investigating whether it is possible to also decrypt the local
databases before they are connected by distributed SQL. A
procedure for testing this will soon be set up between
Helsinki, Stockholm and London. For more details on the
structure of the GenomEUtwin databases see the paper by
Litton et al., in this issue. 
Responsibility and Safety 
Problems of responsibility arise during the entire storage
period of material in human tissue banks. Data protection
should help prevent the risk of a discriminatory use of
information. This problem has worsened in past years,
mainly because of a greater resort to genetic testing. In par-
ticular, medical information disclosed to employers, and
insurance companies could be used to penalize individuals
or groups of individuals. Therefore, human tissue bank
managers will take all the necessary steps in order to
prevent an unauthorized use of information. In this respect
the human tissue bank data managers plays a particularly
important role in preventing unauthorized uses of data.
Human tissue bank managers are entrusted with managing
control activities, compliance with professional codes and
international directives, and ensuring confidentiality. In
order to grant the respect for all the ethical and scientific
requirements in the management of human tissue bank, the
choice of a manager is fundamental (Knoppers et al.,
1998). Ethics committees are entrusted with the main
responsibility of granting their approval for the setting up
of human tissue banks. The Committees should be con-
sulted if the human tissue bank is to be used for purposes
different from those for which it had initially been set up
and for which all participants gave their consent. Although
GenomEUtwin is not a centralized human tissue bank, in
multicenter studies, such as GenomEUtwin, it is appropri-
ate to have a manager for every independent structure. The
role of the manager is also important for monitoring of bio-
logical safety. In fact, the manager will monitor the
observance for safety rules, since biological material can
constitute a potential route for spread of disease. The pro-
tection from biological risks will concern all actors (i.e.,
donors and medical and non-medical staff ). Among other
things, safety requires “traceability” to be granted (i.e., if
need be, it should be possible to track down the donor, at
any time). 
Feedback of Results to Participants
According to the national legislations of each country par-
ticipating in GenomEUtwin, individuals also have the right
to know what data are available on them in the database.
However, each legislation does not provide strict rules for
the feedback of research results to participants on an indi-
vidual basis but states that informed consent should
describe to participants whether they will receive feedback
and the type of feedback they may expect from the
research. In GenomEUtwin the study results are intended
for specific scientific purposes only. Therefore the general
principal is that genotypic or other genetic data will not be
released to participants and consent has been based on this
information. If special circumstances arise regarding the
request for information then these will need to be handled
on a case-by-case basis with input from the Ethics Core in
conjunction with local ethics committees. It must be
emphasized that the information produced by this project
does not meet clinical service laboratory standards.
Therefore any information released must to be replicated
on a fresh sample of the subject’s tissue (this applies to all
samples because of the possibility of mislabeling, but par-
ticularly to DNA samples) in a setting providing: a)
pre-laboratory counseling, b) adequate confirmation by a
clinically-approved laboratory and c) post-laboratory coun-
seling with quality control in place. 
National Legislations
Because GenomEUtwin incorporates data from various
countries it presents an excellent platform for the compari-
son of different legislations and also presents many
challenges that confront multinational studies. Comparison
of legislations is a task to be undertaken by experts versed
in the fine details of international law and will not be
addressed further here. However, for those planning new
projects it is important to meet with local ethics boards,
involve national ethics experts in the project from the
beginning and consider whether your project must address
unique concerns not commonly addressed in the extant
guidelines and documents. Furthermore, it is important to
dedicate time early in project development to mapping out
the similarities and differences in the relevant legislations
from participating countries. This information is essential
to preparation of local ethics applications and consents and
updating of consent forms for new uses of the biological
samples. An early activity of the Ethics Core was to survey
which twin cohorts could share previously collected DNA,
completed genome scans and phenotypic data to
GenomEUtwin. Denmark and the UK were the only coun-
tries in a position to contribute data almost from the start
(Denmark needed to simply amend their approval applica-
tions to cover the transfers of samples). The Danish and
UK scientific ethics committees will approve projects with
broad aims and do not require that every phenotype for
which gene searches may be conducted be specified in the
consent forms. Because the Danish and British twins have
already consented to having their DNA samples used for a
wide variety of studies (e.g., longevity, diabetes, migraine,
osteoporosis, CVD and related risk factors) the phenotypes
of interest in GenomEUtwin were already covered by the
existing approvals from the relevant data protection agen-
cies and ethics boards. The GenomEUtwin Ethics Core is
currently working on summarizing the inter-country differ-
ences in order to proceed with the templates for consent,
updating of consent and ethics applications as described
above. Examples of each country’s consent forms will also
be posted on our website. Even though a common set of
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ethical guidelines reflecting the national regulations of the
participating countries does not exist, and some countries
have not incorporated the EU Directive, all countries
address the same general issues in the form of various
national laws and regulations, which differ primarily with
respect to the extent to which these aspects are legalised.
Although it would be too lengthy to catalogue these differ-
ences, copies of these and related documents are listed by
country on our webpage.14
It is important to note that all data stored within the
twin registries are classified as personal data, including
genetic information when obtained for research purposes
and not for medical treatment. The countries involved in
the GenomEUtwin project have restricted the use of per-
sonal data by law. This law may be differentially referenced
in the different countries (e.g., the Public Administration
Act in Norway, but for clarity we will refer to it as the Data
Protection Act.) Regardless of the recommendations from
the larger community, the law of each country ultimately
determines the restrictions imposed on the researchers. The
distinction between guidelines and actual legislation is well
illustrated by the European Union Data Protection
Directive. This directive, which was passed by the EU in
1995, provides guidelines for the handling of personal data,
which should have been implemented by all Member States
of the European Union by 1998. The set of laws intro-
duced by the Act are the minimum laws required for EU
countries and therefore differences between countries may
still exist as some countries adopt stricter laws than other
countries. All GenomEUtwin participants have either
incorporated the EU Directive in their laws or are in the
process of doing so. However, not all European countries
have presently incorporated these guidelines in their laws;
as such local institutes are bound by their country’s laws
and not by the EU guidelines. Many institutions may
impose additional guidelines for research, resulting in more
strict conditions on research procedures. 
The transfer of information from European Countries
to others countries, as stated in the EU Directive, is legally
restricted to those countries or international institutions
which provide appropriate protection of personal data. The
recent adaptation of the data protection law in Australia
enabled the exchange of personal data between the EU and
Australia. In some cases transfer can still take place, for
instance, if the person involved has given permission for the
transfer. Consequently, the progress of any particular multi-
national project could be hindered depending on the
differences in national legislations of the countries compris-
ing the project.
Empirical Research into Ethical, Legal, Social
and Economic Implications of Human Genetic
and Genomic Research
The importance of establishing empirical research sur-
rounding ethical, legal and social implications of genetic
and genomic research is gaining momentum. As mentioned
above, the planners of the Human Genome Project were
acutely aware of the need to establish an ELSI compo-
nent.15More recently, the Norwegian Functional Genomics
Platform (FUGE) has set aside funds to explore ethical,
legal and social issues of human biobank projects.16 The
function of these ELSI programs is to foster scientific
research that identifies, articulates, and examines ELSI
issues in human genetic studies in parallel with research in
the basic sciences. The research solicited under ELSI pro-
grammes spans a large array of topics surrounding genetic
research (e.g., privacy and fairness in the use and interpreta-
tion of genetic information, informed consent, commercial
use of genetic information, and education). Furthermore,
the scope is very broad, ranging from questions aimed at
understanding individual-level processes to those concerned
with larger sociocultural and societal issues. Such research
will be critical for integrating new knowledge into public
health agendas and health care practice. Most ELSI research
requires expertise in areas (e.g., law, bioethics) and study
designs (e.g., qualitative methods) that are not traditionally
associated with the cohort studies comprising
GenomEUtwin. 
One of the goals of the Ethics Core is to help stimulate
empirical ELSI research. To achieve a fuller understanding
of these ELSI-related issues it is vitally important to
conduct population-based research where the participants
in the genetic study are also part of the ELSI research.
From a research perspective GENOMEUTWIN offers
unique data to analyze ethical, legal, social and cultural
impacts of register-based and genetic studies. The multina-
tional data provide a natural experiment to test cultural
differences, and explore how differences in national stan-
dards and legislation affect subjective understandings of
genetic research and participation in these studies. This
approach will help to map how ethical and social problems
and perceptions of genetic research may vary between dif-
ferent societies. It also will provide the possibility of setting
some accepted standards and codes of practice for genetic
epidemiological studies at the European level. Because
identical twins share all of their genes, a twin design
permits the unique, natural, and extreme study of familial
perception of genetic predisposition. One of the most criti-
cal challenges in the endeavor of ELSI research will be the
identification and articulation of the specific research ques-
tions to be studied and implementation of the most
effective design to answer them. This involves interdiscipli-
nary approaches, often combining areas as diverse as law,
philosophy, psychology and medicine. 
We have outlined key ethics-related issues associated
with GenomEUtwin. Many of these are common to other
genetic and biobanking projects. But some of these issues
are moving targets, as science progresses new ethical consid-
erations will be brought to light, and others may become
trivial. Today’s consensus on immediate issues may quickly
become outdated. Because we are unable to foresee all the
new concerns that will arise research is needed to continue
to articulate these issues and integrate them into public
health agendas. Although the knowledge needed to conduct
ELSI research is seldom part of the normal repertoire of the
geneticists’ toolbox, inclusion of experts who can design
ELSI projects in tandem with genetics research will help
maximize the potential of the data. GenomEUtwin will
produce an enormous amount of information on the inter-
action of genetic and environmental factors contributing to
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human health. But we are also obligated to mine it for the
unique contributions it can make to ELSI research and to
ethical protocols within Europe and, perhaps, worldwide. 
Endnotes
1. Information about this is available from http://www. genome.
gov/10001618
2 see http://www.genomeutwin.org for a description of the core
and its members.
3. These documents will be available shortly on the MORGAM
website http://www.ktl.fi/morgam/
4. The Nuremberg code is available from http://ohsr.od.nih.gov/
nuremberg.php3
5. Available from http://www.wma.net/e/policy/b3.htm
6. The international ethical guidelines for biomedical research
involving human subjects are available from http://www.
cioms.ch/frame_guidelines_nov_2002.htm
7. International Guidelines for Ethical Review of Epidemiological
Studies are available from http://bioetica.bibliotecavirtual-
ensalud.org/I/epidem.htm
8. Convention for the Protection of Human Rights and Dignity
of the Human Being with regard to Application of Biology
and Medicine: Convention on Human Rights and Medicine
is available from http://conventions.coe.int/Treaty/en/
Summaries/  Html/164.htm
9. This report on the ethical, legal, economic and social implica-
tions of human genetics is available from http://europa.eu.int/
comm/research/biosociety/pdf/pe_genetics.pdf
10. This report is available from http://www3.who.int/whosis/
genomics/genomics_report.cfm
11. The UK Biobank project, a proposed large-scale study of
500,000 individuals that will investigate genetic, the environ-
mental and lifestyle factors on common diseases of adulthood,
has followed a somewhat different route and the deliberations
generated from an ethics consultation workshop held in 2002
http://www.ukbiobank.ac.uk/documents/ethics_work.pdf
12. Ethical aspects of human tissue banking is available from
http://europa.eu.int/comm/european_group_ethics/docs/cp
11_en.pdf
13. http://www.fhi.no/hvaskjer/biobanks_workshop.html
14. http://www.genomeutwin.org
15. http://www.genome.gov/10001618
16. http://www.forskningsradet.no/fag/andre/fuge/forskningsmi-
dler2003/
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